Ultimovacs’ melanoma vaccine fails in PhII; Regenxbio’s $140M offering

Plus, news about MindMed, Ven­tyx Bio­sciences, Rakuten Med­ical and Ross Ac­qui­si­tion Corp:

Ul­ti­movacs’ melanoma vac­cine flops in PhII: When added to Bris­tol My­ers Squibb’s Yer­voy and Op­di­vo, the ex­per­i­men­tal UV1 vac­cine did not meet pri­ma­ry or sec­ondary end­points ver­sus the two check­point in­hibitors in un­re­sectable or metasta­t­ic melanoma. The com­pa­ny’s stock $UL­TI.OL, list­ed on the Oslo Stock Ex­change, dropped about 92% on Thurs­day. The biotech said it will con­tin­ue to test UV1 in oth­er com­bi­na­tions and can­cers. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.